GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have transformed weight and diabetes treatment, but they have also raised questions about urinary symptoms and UTIs. The connection is more complicated than “weight-loss drugs cause UTIs.” Diabetes, weight, hydration, constipation, different medication classes, and existing bladder leaks can all affect urinary health.
Updated August 24, 2026
Reviewed By: Dr. A. Goher
Not necessarily.
One of the most common misunderstandings is that all newer weight-loss and diabetes medications increase glucose in the urine and therefore cause urinary tract infections. That is not how GLP-1 medications work.
GLP-1-based medications include semaglutide, sold under brand names such as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. These medications work through hormone pathways that affect appetite, digestion, insulin release, and blood sugar regulation.
They do not work by intentionally sending excess glucose into the urine.
A different class of diabetes medications, called SGLT2 inhibitors, does increase glucose excretion through the kidneys. These include medications such as Jardiance, Farxiga, Invokana, and Steglatro.
That distinction matters when discussing urinary symptoms and infection risk.
GLP-1 medications and SGLT2 inhibitors are sometimes discussed together because both may be prescribed to people with type 2 diabetes, and both can have benefits beyond blood sugar control. But their effects on the urinary tract are quite different.
| Feature | GLP-1-Based Medications | SGLT2 Inhibitors |
|---|---|---|
| Examples | Ozempic, Wegovy, Mounjaro, Zepbound | Jardiance, Farxiga, Invokana, Steglatro |
| Diabetes, obesity/weight management | Diabetes, heart failure, kidney disease | |
| No | Yes | |
| Not a characteristic effect | Increased | |
| No clear consistent increase established | Evidence is mixed; increase is less clear than for genital infections | |
| Common | Less prominent | |
| Possible through nausea, vomiting, diarrhea, or reduced intake | Possible through increased urination |
SGLT2 inhibitors intentionally cause the kidneys to remove glucose through the urine. This can create an environment that increases susceptibility to genital yeast infections.
UTI risk is less straightforward. Some prescribing information warns about urinary tract infections, including rare serious infections, but larger studies have not consistently shown a major increase in ordinary UTIs.
For example, a large 2025 study comparing more than 79,000 people starting SGLT2 inhibitors or GLP-1 medications found nearly identical one-year UTI rates. Genital infections, however, were substantially more common among people taking SGLT2 inhibitors.
The takeaway is not that these medications are unsafe. SGLT2 inhibitors provide important benefits for many people with diabetes, heart failure, and kidney disease. But new urinary or genital symptoms should still be discussed with the prescribing healthcare professional.
Medication is only part of the picture. Diabetes itself can affect urinary health.
When blood glucose levels are high, excess glucose may spill into the urine. Diabetes can also affect nerves responsible for bladder sensation and emptying.
Over time, some people with diabetes may have difficulty completely emptying the bladder. Residual urine that remains in the bladder can increase susceptibility to infection.
Diabetes may therefore contribute to urinary problems in several ways:
If diabetes, urinary incontinence, and recurrent UTIs occur together, it is important not to assume that one medication is automatically responsible. Blood sugar control, bladder emptying, menopause-related changes, medications, and other urinary conditions may all contribute.
Yes. This is an important part of the weight-loss and bladder-health story that is often overlooked.
Excess body weight can increase pressure on the bladder and pelvic floor, and obesity is an established risk factor for urinary incontinence.
Research has shown that even moderate weight loss can improve bladder leakage in women who are overweight or have obesity.
In a randomized clinical trial of 338 women with urinary incontinence, women assigned to an intensive weight-loss program lost an average of about 8% of their body weight over six months. Their weekly incontinence episodes decreased by 47%, compared with a 28% reduction in the control group.
The improvement was particularly strong for stress urinary incontinence. Follow-up research found that benefits for stress leakage remained significant at 12 months.
That means a medication that helps someone achieve meaningful weight loss could potentially have an indirect positive effect on urinary incontinence because of the weight reduction itself, even though the medication is not an incontinence treatment.
It is important to distinguish those two ideas: GLP-1 medications have not been established as treatments for urinary incontinence, but weight loss itself can reduce bladder leakage in some women.
Although GLP-1 medications are not known primarily as bladder medications, side effects can indirectly influence urinary symptoms.
Common GLP-1-related gastrointestinal effects include nausea, vomiting, diarrhea, reduced appetite, and constipation. Any of these can potentially affect hydration or pelvic floor function.
There are also emerging reports of urinary symptoms occurring during GLP-1 treatment, but the evidence is still limited. A 2026 published case report described urinary frequency, painful urination, and other urogenital symptoms in a man taking tirzepatide despite negative infection testing. Symptoms resolved after the medication was discontinued.
A single case report cannot establish that tirzepatide or other GLP-1 medications commonly cause these symptoms. It does show why a new urinary symptom should not automatically be assumed to be a UTI.
If urinary frequency, urgency, burning, or leakage changes after starting or increasing a medication, tell your healthcare provider. Do not stop a prescribed medication without medical guidance.
Weight-loss medication can also intersect with bladder symptoms through hydration and constipation.
Some people taking GLP-1 medications eat and drink considerably less because their appetite is reduced. Nausea, vomiting, or diarrhea can further reduce fluid levels.
For someone who already leaks urine, there may be an additional temptation to drink less because fewer fluids seem like an easy way to avoid accidents.
That can create an unhelpful cycle.
Bladder leaks → drinking less → dehydration and harder stools → constipation and straining → greater stress on the pelvic floor.
Constipation itself can also increase pelvic pressure and may worsen urinary urgency or leakage. We explain this relationship in more detail in our guide to constipation and incontinence.
Unless your healthcare provider has instructed you to restrict fluids, bladder leakage generally should not be managed by deliberately becoming dehydrated.
If bladder leakage continues, it can add another layer to the medication and urinary-health picture.
Some women rely on pads or protective underwear throughout the day. These products are useful for managing accidents, but frequent leakage can mean repeated moisture exposure, more pad changes, odor concerns, and skin irritation.
This may be particularly frustrating for someone already dealing with diabetes, medication side effects, or recurrent urinary symptoms.
Changing wet pads promptly and protecting the skin are important. Our guide to skin irritation and moisture-associated skin damage explains how repeated urine exposure can affect the skin.
But pads address leakage after it occurs. If incontinence is ongoing, treating the bladder leakage itself may reduce the need for constant protection.
Contact your healthcare provider if urinary symptoms begin or noticeably change after starting a weight-loss or diabetes medication.
Symptoms worth discussing include:
A healthcare professional can help determine whether the symptoms are caused by infection, the medication, diabetes, dehydration, an underlying bladder condition, or another problem.
Do not stop prescribed weight-loss or diabetes medication on your own because of urinary symptoms.
Elitone does not treat diabetes, medication side effects, or urinary tract infections. Its role is to treat urinary incontinence when bladder leakage remains part of the picture.
This can be especially relevant for women who are already working on weight and metabolic health. Weight loss itself may reduce stress urinary incontinence, but improvement is not always complete, and pelvic floor weakness may still contribute to leakage.
Elitone is an FDA-cleared external treatment that uses neuromuscular electrical stimulation to produce repeated pelvic floor contractions and strengthen the muscles responsible for bladder and urethral support.
In a 2024 study of women with obesity and urinary incontinence, adding pelvic floor exercises to a weight-management rehabilitation program produced greater improvements in leakage and quality of life than weight management alone. This supports the idea that weight reduction and pelvic floor treatment can be complementary rather than either-or approaches.
For women already managing weight-loss medications, diabetes treatment, or other health conditions, Elitone also offers a non-drug approach to urinary incontinence. Treatment is external and performed at home without adding another medication to the daily routine.
The goal does not have to be choosing between weight loss and bladder treatment. When both excess weight and pelvic floor weakness contribute to leakage, addressing both may provide the greatest opportunity for improvement.
Current evidence does not show that semaglutide medications such as Ozempic or Wegovy routinely cause UTIs. They do not work by increasing glucose in the urine. New urinary symptoms should still be evaluated because diabetes, dehydration, infection, bladder conditions, and other medications may be involved.
Tirzepatide is not primarily associated with urinary side effects, although emerging case reports describe unusual urinary symptoms in individual patients. More research is needed. New or persistent urinary symptoms should be discussed with the prescribing healthcare professional.
SGLT2 inhibitors such as Jardiance, Farxiga, Invokana, and Steglatro lower blood glucose partly by causing the kidneys to excrete more glucose in urine. GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound do not work this way.
SGLT2 inhibitors clearly increase the risk of genital fungal infections. The relationship with urinary tract infections is less consistent. Some prescribing information warns about UTIs, including rare serious infections, while large studies have not consistently found a substantial increase in ordinary UTIs.
Yes. Weight loss has been shown to reduce urinary incontinence in women who are overweight or have obesity. In one randomized trial, women who lost about 8% of their body weight experienced a 47% reduction in weekly incontinence episodes after six months.
GLP-1 medications are not established treatments for urinary incontinence. However, if they help someone achieve meaningful weight loss, the reduction in body weight may indirectly improve bladder leakage because excess weight is a risk factor for incontinence.
Yes. Concentrated urine can irritate the bladder in some people, and inadequate fluids can contribute to constipation. People with bladder leaks should generally not deliberately dehydrate themselves unless a healthcare professional has recommended fluid restriction for another medical reason.
Elitone is a non-drug treatment for urinary incontinence and does not work through the same pathways as GLP-1 medications. Follow Elitone’s instructions for use and discuss any individual medical concerns or contraindications with your healthcare professional.
Receive educational resources, exclusive offers, and new product information.
